The role of metabolism in cancer growth and cell survival is an area of growing interest. The shift in glucose metabolism from oxidative phosphorylation to lactate production for energy generation (the Warburg Effect) is a well-known metabolic hallmark of tumor cells, and several key signaling pathways, oncogenes, and tumor suppressors―including Akt, mTor, c-myc, and p53―are linked to the increase in glycolysis seen in tumor cells. Beyond fulfilling energy requirements, highly proliferative cells also need to produce excess lipids, nucleotides, and amino acids for the creation of new biomass. In order to do this, a number of metabolic adaptations occur in cancer cells that help generate these metabolites, fuel growth, and may also aid in the evasion of apoptosis. This webinar will delve into these issues, with the help of our three thought leaders.
During the webinar, our panel of experts will:
• Discuss the critical importance of understanding metabolism in the context of cell health and function
• Elucidate the metabolic pathways thought to be involved in tumorigenesis and other diseases
• Share new discoveries and trends in research on cancer metabolism
• Answer your questions live during the webinar!
Matthew Vander Heiden, M.D., Ph.D.
Massachusetts Institute of Technology
Dr. Vander Heiden is the Howard S. and Linda B. Stern Assistant Professor in the Koch Institute for Integrative Cancer Research and the Department of Biology at the Massachusetts Institute of Technology (MIT). He is also an Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Vander Heiden received his M.D. and Ph.D. degree from the University of Chicago working in the laboratory of Dr. Craig Thompson. He completed clinical training in Internal Medicine at the Brigham and Women’s Hospital, an oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital program, prior to completing a postdoctoral fellowship at Harvard Medical School with Dr. Lewis Cantley. He maintains a limited medical oncology practice at Dana-Farber in addition to his research efforts at the Koch Institute at MIT. His research is focused on understanding how cell metabolism is regulated to support proliferation.
Morris J. Birnbaum, M.D., Ph.D.
University of Pennsylvania
Dr. Birnbaum completed his undergraduate, graduate, and medical training at Brown University in Providence, Rhode Island in the United States before moving to San Francisco to carry out his postdoctoral studies at the University of California. Following an associate professorship at Harvard Medical School, he moved to the University of Pennsylvania as Professor of Medicine. Dr. Birnbaum is currently the associate dean for Biomedical Cores and the associate director of the Institute for Diabetes, Obesity, and Metabolism. The research in his laboratory involves the study of the mechanism of insulin action, metabolism, and how organisms respond to both a deficit and a surfeit of food, with a particular focus on insulin-dependent metabolic pathways. Dr. Birnbaum was elected to membership in the Association of American Physicians in 2003 and was made a fellow of AAAS in 2007. He recently stepped down as deputy editor of the Journal of Clinical Investigation.
Brendan D. Manning, Ph.D.
Harvard University, School of Public Health
Dr. Manning undertook his doctoral training in the laboratory of Dr. Michael Snyder at Yale University, where he worked on basic mechanisms of mitosis and cell division in budding yeast. Dr. Manning then joined the laboratory of Dr. Lewis Cantley at Harvard Medical School to study mammalian signal transduction pathways for his postdoctoral research. In 2004, Dr. Manning joined the faculty of the then-newly established Department of Genetics and Complex Diseases at the Harvard School of Public Health, where he is now an associate professor. The ongoing work in his laboratory is delineating the complex molecular wiring and downstream functions of disease-associated signaling networks, with a focus on the interface between metabolism and cancer. This research is revealing novel therapeutic strategies to manipulate these networks for the treatment of common human diseases.
Moderator: Sean Sanders, Ph.D.
Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Editor for Custom Publishing for the journal Science and Program Director for Outreach.
For related product information, go to: http://www.cellsignal.com